Book a Meeting

Non-Fucosylated Anti-Human B7-H3 (Omburtamab) Therapeutic Antibody (CAT#: BioBet-1824ZP) Datasheet

Target
B7-H3
Isotype
IgG1
Description
Non-Fucosylated Anti-Human B7-H3 (Omburtamab) is a glycosylation-modified therapeutic biobetter antibody.
Indication
CNS/leptomeningeal metastases from neuroblastoma
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced B7-H3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD276
Full Name
CD276 molecule
Background
The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. Additionally, it was observed that the 3' UTR of this transcript contains a target site for miR29 microRNA, and there is an inverse correlation between the expression of this protein and miR29 levels, suggesting regulation of expression of this gene product by miR29. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Alternative Names
CD276; CD276 molecule; B7H3; B7-H3; B7RP-2; 4Ig-B7-H
Gene ID
80381
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Omburtamab
Host
Humanized afucosylated
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Indication
CNS/leptomeningeal metastases from neuroblastoma

Related Products

Non-Fucosylated Anti-Human B7-H3 (DS-5573a) Therapeutic Antibody (CAT#: BioBet-1791ZP)
ADCC-Enhanced Anti-Human B7-H3 (Omburtamab) Antibody (CAT#: BioBet-CB-086LX)
Non-Fucosylated Anti-Human B7-H3 (MGA271) Therapeutic Antibody (CAT#: BioBet-654ZP)
ADCC-Enhanced Anti-Human B7-H3 (131I-omburtamab) Antibody (CAT#: BioBet-CB-057LX)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany